Lineage Cell Therapeutics (LCTX) EPS (Basic) Growth (3y) (2013 - 2026)
Lineage Cell Therapeutics (LCTX) EPS (Basic) Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 53.55% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 37.73% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.29% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -2.89% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 86.43% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Lineage Cell Therapeutics | 267.08 Mn | 203.18 Mn | 1.73 Mn | 8.80% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.80% |
| Dec 31, 2025 | 12.09% |
| Sep 30, 2025 | -32.03% |
| Jun 30, 2025 | -35.17% |
| Mar 31, 2025 | 91.03% |
| Dec 31, 2024 | 95.43% |
| Sep 30, 2024 | 30.20% |
| Jun 30, 2024 | 89.99% |
| Mar 31, 2024 | -57.81% |
| Dec 31, 2023 | -26.08% |
| Sep 30, 2023 | 8.26% |
| Jun 30, 2023 | 11.22% |
| Mar 31, 2023 | 22.80% |
| Dec 31, 2022 | -26.01% |
| Sep 30, 2022 | 33.86% |
| Jun 30, 2022 | 43.14% |
| Mar 31, 2022 | -468.74% |
| Dec 31, 2021 | -681.16% |
| Sep 30, 2021 | -27.84% |
| Jun 30, 2021 | -840.63% |